{"organizations": [], "uuid": "c2f0303de41595347d501eeb558907d5b3f623e6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ziopharm-oncology-q4-loss-per-shar/brief-ziopharm-oncology-q4-loss-per-share-0-13-idUSASB0C8FX", "country": "US", "domain_rank": 408, "title": "BRIEF-ZIOPHARM Oncology Q4 Loss Per Share $0.13", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T23:26:00.000+02:00", "replies_count": 0, "uuid": "c2f0303de41595347d501eeb558907d5b3f623e6"}, "author": "", "url": "https://www.reuters.com/article/brief-ziopharm-oncology-q4-loss-per-shar/brief-ziopharm-oncology-q4-loss-per-share-0-13-idUSASB0C8FX", "ord_in_thread": 0, "title": "BRIEF-ZIOPHARM Oncology Q4 Loss Per Share $0.13", "locations": [], "entities": {"persons": [{"name": "reu", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "ziopharm oncology inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1, 2018 / 9:27 PM / Updated 11 minutes ago BRIEF-ZIOPHARM Oncology Q4 Loss Per Share $0.13 Reuters Staff March 1 (Reuters) - ZIOPHARM Oncology Inc: * ZIOPHARM ONCOLOGY REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE * Q4 LOSS PER SHARE $0.13 * ‍ZIOPHARM BELIEVES ITS CURRENT RESOURCES WILL BE SUFFICIENT TO FUND ITS CURRENTLY PLANNED OPERATIONS INTO Q4 OF 2018​ * Q4 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-01T23:26:00.000+02:00", "crawled": "2018-03-01T23:42:24.040+02:00", "highlightTitle": ""}